FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895053555> ?p ?o ?g. }

• W2895053555 endingPage "5573" @default.
• W2895053555 startingPage "5565" @default.
• W2895053555 abstract "Autoreactive B cells are thought to play a pivotal role in many autoimmune diseases. Rheumatoid arthritis (RA) is an autoimmune disease affecting ∼1% of the Western population and is hallmarked by the presence of anticitrullinated proteins antibodies (ACPA) produced by autoreactive B cells. We intend to develop a method to target and selectively eliminate these autoreactive B cells using a sequential antigen prodrug targeting strategy. As ACPA-expressing B cells are thought to play essential roles in RA-disease pathogenesis, we used this B cell response as a prototype to analyze the feasibility to generate a construct consisting of a biologically silenced, that is, blocked, antigen connected to a cytotoxic prodrug. Blocking of the antigen is considered relevant as it is anticipated that circulating autoantibodies will otherwise clear the antigen-prodrug before it can reach the target cell. The antigen-prodrug can only bind to the autoantigen-specific B cell receptor (BCR) upon enzymatic removal of the blocking group in close proximity of the B cell surface. BCR binding ultimately induces antigen-specific cytotoxicity after internalization of the antigen. We have synthesized a cyclic citrullinated peptide (CCP) antigen suitable for BCR binding and demonstrated that binding by ACPA was impaired upon introduction of a carboxy- p-nitrobenzyl (CNBz) blocking group at the side chain of the citrulline residue. Enzymatic removal of the CNBz moiety by nitroreductase fully restored citrulline-specific recognition by both ACPA and ACPA-expressing B cells and showed targeted cell death of CCP-recognizing B cells only. These results mark an important step toward antigen-specific B cell targeting in general and more specifically in RA, as successful blocking and activation of citrullinated antigens forms the basis for subsequent use of such construct as a prodrug in the context of autoimmune diseases." @default.
• W2895053555 created "2018-10-12" @default.
• W2895053555 creator A5015901323 @default.
• W2895053555 creator A5023177378 @default.
• W2895053555 creator A5033153014 @default.
• W2895053555 creator A5061582188 @default.
• W2895053555 creator A5081889079 @default.
• W2895053555 creator A5085046817 @default.
• W2895053555 date "2018-10-05" @default.
• W2895053555 modified "2023-10-18" @default.
• W2895053555 title "Sequential Prodrug Strategy To Target and Eliminate ACPA-Selective Autoreactive B Cells" @default.
• W2895053555 cites W1978407833 @default.
• W2895053555 cites W1983748607 @default.
• W2895053555 cites W1991318621 @default.
• W2895053555 cites W1992505602 @default.
• W2895053555 cites W1995883701 @default.
• W2895053555 cites W2011624861 @default.
• W2895053555 cites W2013573826 @default.
• W2895053555 cites W2014069721 @default.
• W2895053555 cites W2017716166 @default.
• W2895053555 cites W2020247473 @default.
• W2895053555 cites W2035000560 @default.
• W2895053555 cites W2038398254 @default.
• W2895053555 cites W2043028214 @default.
• W2895053555 cites W2046072905 @default.
• W2895053555 cites W2055707343 @default.
• W2895053555 cites W2061393217 @default.
• W2895053555 cites W2084064203 @default.
• W2895053555 cites W2101254888 @default.
• W2895053555 cites W2102321925 @default.
• W2895053555 cites W2102378249 @default.
• W2895053555 cites W2109578241 @default.
• W2895053555 cites W2114652063 @default.
• W2895053555 cites W2118994799 @default.
• W2895053555 cites W2127411681 @default.
• W2895053555 cites W2132841358 @default.
• W2895053555 cites W2143237309 @default.
• W2895053555 cites W2147843944 @default.
• W2895053555 cites W2158434979 @default.
• W2895053555 cites W2160763791 @default.
• W2895053555 cites W2264949505 @default.
• W2895053555 cites W2269217719 @default.
• W2895053555 cites W2276292141 @default.
• W2895053555 cites W2409512187 @default.
• W2895053555 cites W2410883536 @default.
• W2895053555 cites W2415836897 @default.
• W2895053555 cites W2515724475 @default.
• W2895053555 cites W2531009503 @default.
• W2895053555 cites W2562348661 @default.
• W2895053555 cites W2610907738 @default.
• W2895053555 cites W2724220888 @default.
• W2895053555 cites W2754135383 @default.
• W2895053555 cites W2888114826 @default.
• W2895053555 cites W4210968471 @default.
• W2895053555 doi "https://doi.org/10.1021/acs.molpharmaceut.8b00741" @default.
• W2895053555 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6282105" @default.
• W2895053555 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30289723" @default.
• W2895053555 hasPublicationYear "2018" @default.
• W2895053555 type Work @default.
• W2895053555 sameAs 2895053555 @default.
• W2895053555 citedByCount "8" @default.
• W2895053555 countsByYear W28950535552019 @default.
• W2895053555 countsByYear W28950535552020 @default.
• W2895053555 countsByYear W28950535552021 @default.
• W2895053555 countsByYear W28950535552022 @default.
• W2895053555 countsByYear W28950535552023 @default.
• W2895053555 crossrefType "journal-article" @default.
• W2895053555 hasAuthorship W2895053555A5015901323 @default.
• W2895053555 hasAuthorship W2895053555A5023177378 @default.
• W2895053555 hasAuthorship W2895053555A5033153014 @default.
• W2895053555 hasAuthorship W2895053555A5061582188 @default.
• W2895053555 hasAuthorship W2895053555A5081889079 @default.
• W2895053555 hasAuthorship W2895053555A5085046817 @default.
• W2895053555 hasBestOaLocation W28950535551 @default.
• W2895053555 hasConcept C108215921 @default.
• W2895053555 hasConcept C147483822 @default.
• W2895053555 hasConcept C154317977 @default.
• W2895053555 hasConcept C157695867 @default.
• W2895053555 hasConcept C159654299 @default.
• W2895053555 hasConcept C163764329 @default.
• W2895053555 hasConcept C185592680 @default.
• W2895053555 hasConcept C195616568 @default.
• W2895053555 hasConcept C202751555 @default.
• W2895053555 hasConcept C203014093 @default.
• W2895053555 hasConcept C2776090121 @default.
• W2895053555 hasConcept C2777468819 @default.
• W2895053555 hasConcept C2778453870 @default.
• W2895053555 hasConcept C2779129087 @default.
• W2895053555 hasConcept C2908647359 @default.
• W2895053555 hasConcept C48632299 @default.
• W2895053555 hasConcept C515207424 @default.
• W2895053555 hasConcept C55493867 @default.
• W2895053555 hasConcept C71924100 @default.
• W2895053555 hasConcept C86803240 @default.
• W2895053555 hasConcept C8891405 @default.
• W2895053555 hasConcept C99454951 @default.
• W2895053555 hasConceptScore W2895053555C108215921 @default.
• W2895053555 hasConceptScore W2895053555C147483822 @default.

• next